Xenon PharmaceuticalsXENE
Recorded

Xenon Pharmaceuticals Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration29 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Paul MatteisAnalyst

All right, great. Thanks everyone for sticking around for the last fireside chat of the day. Happy to be here with the Xenon Pharmaceuticals management team, Ian Mortimer, President and CEO, and Tucker Kelly, Chief Financial Officer. I'm sure folks who are listening in or here in person know the company decently well, but maybe, guys, you could just kind of give a quick rundown of the recent updates. You submitted the NDA, right? You've got some data coming up the end of this year. Recently made some progress with pain, but maybe just give us some highlights and then we'll do Q&A.

Ian MortimerPresident and CEO

Yeah, sounds great. Thank you.

Ian MortimerPresident and CEO

Thanks, Paul, for having us. We had earnings this week on Monday, so we gave a really good update there, but I'll provide a quick overview. We really think about the business in three main components: azetukalner in epilepsy, the expansion of azetukalner into psychiatry, and then the emerging pain portfolio, where we've had some updates across all of those over the last couple of months. We'll spend some time in Q&A just on the profile of azetukalner in epilepsy. Obviously, we've completed two large randomized placebo-controlled studies. I think the profile in epilepsy is excellent from an efficacy, novel mechanism, ease of use attributes. We had our X-TOLE2 data earlier this year, and that set us up to file the new drug application in September.

Ian MortimerPresident and CEO

It is really exciting to be now in front of the agency in terms of filing our NDA and really getting ready to commercialize this medicine. We spent a lot of time thinking about how can we do this differently in a market where there are lots of generic drugs, but I think there is a need for innovation, and I think we are bringing innovation to the epilepsy community. We have been looking at azetukalner in psychiatry as well. We can go back through a little bit of the history. We had a voluntary pause on our phase III program in September. The update we provided this week is that we will unblind that first phase III MDD study, which we are calling X-NOVA2, and we will see data next month. I think that is going to be really important to inform.

Ian MortimerPresident and CEO

Now we will have unblinded efficacy and safety data to inform the program going forward. That is next month, and then we will be able to talk about that moving forward. I think we have made excellent progress on the pain portfolio. We were at an international pain medical congress in October where we were able to show the phase I data from our two assets. One is called XEN1701, which is a NaV1.7 inhibitor, and the second is XEN1120, which is a Kv7 modulator. Both of them met kind of the TPP or what we thought about the profile coming out of phase I, and both of those molecules will enter phase II proof of concept studies in acute pain next year.

Paul MatteisAnalyst

Awesome. Great. I want to spend mostly time on epilepsy and pain, but maybe let us just cover this upcoming MDD update. Maybe to start, what more do you plan on disclosing around the safety profile with the top line update?

Ian MortimerPresident and CEO

Yeah, I think it is probably worth maybe to take a few steps back.

Ian MortimerPresident and CEO

Sure to frame it, then we'll talk about what we'll have in December.

Ian MortimerPresident and CEO

We believe that Kv7 modulation, and specifically ezogabine, have antidepressant effects. I think there's enough data out there pre-clinically and clinically. There's been four different clinical studies run with this mechanism. All have shown separation. The three placebo-controlled studies all showed separation between active and placebo. When we ran our phase II study, which was a smaller proof of concept study, just over 50 subjects per arm, two doses versus placebo, that was our X-NOVA study we unblinded a couple of years ago. We saw clear separation on both MADRS and HAMD-17, the two scales of clinical depression, and also a clinical scale of anhedonia, which we call the SHAPS scale. 10 milligrams, which was the low dose, outperformed placebo, and 20 milligrams, the higher dose, outperformed 10 milligrams.

Ian MortimerPresident and CEO

Clear dose response, clear separation with placebo. What was interesting about the study when we unblinded is the safety profile was really benign in that phase II study. I remember at the time talking with many people on the street and talking with you as well, that the tolerability was better than we expected. It was those data that we now moved into a large phase III program. What we found in phase III, blinded data, but what we're seeing in the phase III psychiatry program, it looks like the safety profile is more similar to what we see in the epilepsy studies, and not what we were seeing in the phase II X-NOVA study. Still blinded data, but we are seeing some of the adverse events that are more consistent with the epilepsy profile.

Ian MortimerPresident and CEO

We've had lots of questions on, "Are you seeing new stuff or different stuff?" No, we're seeing what we would see in the epilepsy profile, and we've been in well over 1,000 patients in epilepsy. We've had patients that have been on the medicine for more than five years, so I think we have a really good understanding. What we'll see next month when we unblind is obviously the efficacy data. The primary endpoint is being HAMD-17 at six weeks. We'll also look at SHAPS, which is a scale of anhedonia, but we will have the unblinded safety data. I think anyone that still has outstanding questions on the safety profile of the drug as it relates in psychiatry, we'll be able to answer all of those questions.

Ian MortimerPresident and CEO

We'll provide those data publicly, then we can move forward either to continue to develop in psychiatry or we really focus azetukalner on the epilepsy launch.

Paul MatteisAnalyst

Yep. Okay. Makes sense. On the safety side, I think the one AE that has spooked people the most, because at face it can vary in the level of severity of it, is psychosis. Can you talk a little bit more about what you saw there? I guess, for investors who say, "Okay, hey, this happened. Is there read-through to epilepsy?" Maybe you can give a little bit of context on other AEDs and the sort of background rates of these psychiatric events and sort of how AZK compares.

Ian MortimerPresident and CEO

Sure. If we look at potassium channel modulation overall, or ezogabine specifically, this is a very potent mechanism, and this is a very potent drug. We see, as we're trying to dampen hyperexcitability in the brain, you're going to see adverse events. What's very clear now that we've looked at multiple doses in phase II and phase III, in epilepsy, we've looked at 10, 15, 20, and 25 milligrams. The 10 and 15 milligrams of the drug look very placebo-like, very difficult to indistinguish between active and placebo at those two dose levels. As you move to 20 and 25 milligrams, you get better efficacy. It's almost linear in terms of seizure reduction, and you do see higher rates of adverse events. The most common adverse events for a drug that's very potent and active in the CNS are things like dizziness, somnolence, fatigue, and headache.

Ian MortimerPresident and CEO

Those would be the adverse events that we see above 10%. If we go kind of below 10%, you start to see, as you dampen hyperexcitability, you see some events, things like word finding or confusion or concentration difficulties. Again, very consistent with ezogabine at higher doses and consistent with other anti-seizure medicines. Then you see the really rare events, and these can be SAEs, and they're usually like one patient in a study or two patients in a study, depending on the event. Then you see these rare events of a psychiatric adverse event, like a psychosis. This has all been published with the molecule. Even if you go back to the ezogabine days, it would be consistent with that. Even the most highly prescribed anti-seizure medicine today, which is levetiracetam or KEPPRA, has just under a 1% rate of psychosis.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day